Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US

IMPORTANCE: Randomized clinical trials have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) cause significant weight loss and reduce cardiovascular events in patients with type 2 diabetes (T2D). Black patients have a disproportionate burden of obesity and cardiovascular disease and...

Descripción completa

Detalles Bibliográficos
Autores principales: Eberly, Lauren A., Yang, Lin, Essien, Utibe R., Eneanya, Nwamaka D., Julien, Howard M., Luo, Jing, Nathan, Ashwin S., Khatana, Sameed Ahmed M., Dayoub, Elias J., Fanaroff, Alexander C., Giri, Jay, Groeneveld, Peter W., Adusumalli, Srinath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796881/
https://www.ncbi.nlm.nih.gov/pubmed/35977298
http://dx.doi.org/10.1001/jamahealthforum.2021.4182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796881/
https://www.ncbi.nlm.nih.gov/pubmed/35977298
http://dx.doi.org/10.1001/jamahealthforum.2021.4182

Ejemplares similares